71 reports

INCREASING INCIDENCES FOR KIDNEY CANCERS ##. ##. ##.

  • Cancer
  • Renal Cancer
  • Therapy
  • World
  • Forecast
  • Global Kidney Cancer Drugs Market
  • Global Kidney Cancer Drugs Market
  • Renal Cancer
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer Inc.

Welcome to having the world of renal cancer at your fingertips with " Target Atlas in Renal Cancer: A Competitive Outlook"!

  • Cancer
  • Renal Cancer

Until 1980’s, the treatment of kidney cancer included surgical removal of the kidneys.

  • Cancer
  • Renal Cancer
  • Therapy
  • World
  • Market Size
  • TRENDS IN THE FIVE-YEAR RELATIVE SURVIVAL (%) OF KIDNEY CANCERS IN THE 8MM, BOTH SEXES,
  • presents the temporal trends in the age-adjusted incidence rate of kidney cancers in the
  • Renal Cancer
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Pfizer Inc.
  • Roche Group
  • The following is the list of drugs in phase 2 or phase 3 development for renal cancer-related indications.
  • Forecast
  • Renal Cancer
  • World
  • Exelixis, Inc.
  • Merck & Co., Inc.
  • Rexahn Pharmaceuticals, Inc.
  • Trends in the Five-Year Relative Survival (%) of Kidney Cancers in the 8MM, Both Sexes,
  • presents the temporal trends in the age-adjusted incidence rate of kidney cancers in the
  • Cancer
  • Pathology
  • Renal Cancer
  • China
  • Forecast

An Introduction to Renal Cancer Treatments ##. ## What is Renal Cancer?

  • Renal Cancer
  • Therapy
  • United States
  • World
  • Market Size

Renal cell cancer

4546 5000 3864
  • RCC IS THE MOST COMMON TYPE OF KIDNEY CANCER
  • EXTRACTING INCIDENCE RATE DATA FOR JAPAN, FRANCE, SPAIN, AND THE UK
  • Renal Cancer
  • Asia
  • Europe
  • Japan
  • World
  • Overviews
  • Chapter IV
  • Renal Cancer
  • China
  • Demand
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd
  • Overviews
  • CHAPTER III KIDNEY CANCER TREATMENT DRUGS INDUSTRY ASSESSMENTS
  • Renal Cancer
  • China
  • Demand
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd
  • CHAPTER III KIDNEY CANCER TREATMENT DRUGS INDUSTRY ASSESSMENTS
  • Market Size
  • Renal Cancer
  • China
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd
  • Roche Group
  • KIDNEY CANCER (RENAL CELL CANCER)
  • KIDNEY CANCER (RENAL CELL CANCER)
  • Cell Therapy
  • Renal Cancer
  • North America
  • United States
  • Product Initiative

Kidney cancer also called renal cancer is a disease in which kidney cells become malignant (cancerous) and grows out of control, forming a tumor.

  • Cancer
  • Pathology
  • Renal Cancer
  • Product Initiative
  • 25 May 2012
  • COMPANY PRESS RELEASES RELATED TO VOTRIENT
  • Renal Cancer
  • Europe
  • United States
  • Novartis AG
  • Pfizer Inc.
  • 5.17.1 DISEASE OVERVIEW

KIDNEY.

  • Renal Cancer
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Roche Group
  • METASTATIC BREAST CANCER

APPROXIMATELY ##% OF THE KIDNEY CANCER PATIENTS SUFFER FROM RCC.

  • Renal Cancer
  • United States
  • Agenus Inc.
  • Incyte Corporation
  • Merck & Co., Inc.
  • Kidney Cancer - Discontinued Products
  • Kidney Cancer - Dormant Projects
  • Cancer
  • Pathology
  • Renal Cancer
  • Jul 10, 2017: Kidney Cancer UK delighted NICE recommends cabozantinib on NHS for kidney cancer patients
  • Jun 12, 2017: Scotland first in UK to make Cabometyx (cabozantinib) routinely available for individuals living with advanced kidney cancer
  • Hepatitis
  • Renal Cancer
  • United States
  • Company
  • Exelixis, Inc.
  • 04/21/2017: ARMO BIOSCIENCES ANNOUNCES CLINICAL DATA PRESENTATION FOR IMMUNOTHERAPY AM0010 AT THE 12TH EUROPEAN INTERNATIONAL KIDNEY CANCER SYMPOSIUM
  • Pharmaceutical
  • Renal Cancer
  • United States
  • Company
  • ARMO Biosciences, Inc.
  • JUL 05, 2017: COMBO IMMUNOTHERAPY MAY HERALD NEW STANDARD OF CARE FOR KIDNEY CANCER
  • JUL 08, 2017: ALLIGATOR CONTRACTS BIOINVENT FOR PROCESS DEVELOPMENT AND CGMP MANUFACTURING OF THE IMMUNOONCOLOGY DRUG CANDIDATE ADC-1015
  • Oncology
  • Renal Cancer
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company
  • ULTRA-SENSITIVE ASSAY - KIDNEY CANCER
  • Ultra-Sensitive Assay - Kidney Cancer - Product Description
  • Biotechnology
  • In Vitro Diagnostic Reagent
  • Nanobiotechnology
  • Renal Cancer
  • Nanosphere, Inc.
  • Nov 23, 2015: FDA approves Opdivo to treat advanced form of kidney cancer
  • Nov 05, 2015: Rexahn Pharmaceuticals Reports Interim Clinical Data for Archexin at the 14th International Kidney Cancer Symposium
  • Pharmaceutical
  • Renal Cancer
  • Therapy
  • United States
  • Product Initiative
  • Oct 22, 2015: Exelixis Initiates Rolling Submission of U.S. New Drug Application for Cabozantinib for the Treatment of Advanced Kidney Cancer
  • Apr 26, 2016: Diplomat to Dispense CABOMETYX (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma
  • Renal Cancer
  • United States
  • Market Description
  • Product Initiative
  • Exelixis, Inc.
  • KIDNEY CANCER (RENAL CELL CANCER), METASTATIC RENAL CELL CARCINOMA
  • KIDNEY CANCER (RENAL CELL CANCER), METASTATIC RENAL CELL CARCINOMA
  • Clinical Trial
  • Hospital
  • Renal Cancer
  • World
  • Pfizer Inc.
  • JUN 12, 2017: SCOTLAND FIRST IN UK TO MAKE CABOMETYX (CABOZANTINIB) ROUTINELY AVAILABLE FOR INDIVIDUALS LIVING WITH ADVANCED KIDNEY CANCER
  • JUN 12, 2017: EXELIXIS ANNOUNCES INITIATION OF PHASE 1B TRIAL OF CABOZANTINIB IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
  • Oncology
  • Renal Cancer
  • World
  • Product Initiative
  • Exelixis, Inc.
  • JUN 12, 2017: SCOTLAND FIRST IN UK TO MAKE CABOMETYX (CABOZANTINIB) ROUTINELY AVAILABLE FOR INDIVIDUALS LIVING WITH ADVANCED KIDNEY CANCER
  • MELANOMA
  • Renal Cancer
  • United States
  • World
  • Product Initiative
  • Exelixis, Inc.
  • MAR 02, 2012: PHARMAC TO FUND GSK'S KIDNEY CANCER DRUG, VOTRIENT
  • AUG 21, 2013: PAZOPANIB SHOWS BETTER QUALITY-OF-LIFE IN ADVANCED KIDNEY CANCER
  • Cancer
  • Renal Cancer
  • Europe
  • Product Initiative
  • Novartis AG
  • Product Approvals
  • Deal Sub Type
  • Pharmaceutical
  • Renal Cancer
  • United States
  • Company
  • GlobalData's company
  • CONTINUATIVE STUDY OF MGN-1601 IN RENAL CANCER
  • KIDNEY CANCER (RENAL CELL CANCER), PROSTATE CANCER
  • Clinical Trial
  • Hospital
  • Renal Cancer
  • World
  • Pfizer Inc.